In this issue of European Heart Journal: Acute Cardiovascular Care, Guerra et al. present results of the systematic review and meta-analysis on over half a million of patients with recent acute coronary syndrome (ACS) that aimed to assess the value of the CHA 2 DS 2 -VASc scale (congestive heart failure, hypertension, age ⩾75 years, diabetes mellitus, stroke/transient ischaemic attack (TIA), vascular disease, age 65-74 years, sex category (female)) in stroke prediction, irrespective of atrial fibrillation (AF) history. 1 The authors found that each component of the CHA 2 DS 2 -VASc strata was associated with a similarly increased risk of stroke/thromboembolism as previously reported in AF. Guerra et al. suggest that the predictive value of the CHA 2 DS 2 -VASc score is perhaps disconnected from AF, with AF being only one of the stroke risk factors, and that this scoring system may be validated in the ACS population to guide stroke prevention therapies.
The study
In this issue of European Heart Journal: Acute Cardiovascular Care, Guerra et al. present results of the systematic review and meta-analysis on over half a million of patients with recent acute coronary syndrome (ACS) that aimed to assess the value of the CHA 2 DS 2 -VASc scale (congestive heart failure, hypertension, age ⩾75 years, diabetes mellitus, stroke/transient ischaemic attack (TIA), vascular disease, age 65-74 years, sex category (female)) in stroke prediction, irrespective of atrial fibrillation (AF) history. 1 The authors found that each component of the CHA 2 DS 2 -VASc strata was associated with a similarly increased risk of stroke/thromboembolism as previously reported in AF. Guerra et al. suggest that the predictive value of the CHA 2 DS 2 -VASc score is perhaps disconnected from AF, with AF being only one of the stroke risk factors, and that this scoring system may be validated in the ACS population to guide stroke prevention therapies.
The stroke/TIA rate is 1.3% in the present analysis (nine months median observation). This is not high, considering the fact that 11.2% of patients had AF previously diagnosed and the vast majority of patients must have had a high CHA 2 DS 2 -VASc score (although mean/median score was not provided). Unfortunately, no data on patients with stroke were provided, especially on what proportion actually had AF. Importantly, one in three patients with ischaemic stroke and over 80% of those with cardioembolic stroke may have had underlying AF. 2 AF may also play a role in many cases (approximately a third) of cryptogenic strokes, which account for 25% of all strokes.
AF has been well established as a systemic disease that increases thrombogenesis by endothelial or endocardial damage/dysfunction, abnormal blood stasis as well as abnormal haemostasis, platelet function and fibrinolysis (Virchow's triad). 3 Oral anticoagulation (OAC) reduces stroke risk in AF by 64% and mortality by 26% compared with placebo/control and, thus, OAC is recommended in all AF patients at risk of stroke exceeding the annual rate of 1.0% (without treatment), when considering the net clinical benefit of stroke risk reduction against risk of bleeding. 4 However, the benefits of OAC therapy has not been proven for any other component risk factors of the CHA 2 DS 2 -VASc score. For example, a recent Cochrane systematic review and meta-analysis of patients with heart failure and sinus rhythm (with no AF) did not show any benefit of OAC versus antiplatelet therapy for all-cause mortality reduction. Although therapy with warfarin was associated with a 20% decrease in non-fatal cardiovascular events, it led to a two-fold increase in bleeding events. 5 
CHA 2 DS 2 -VASc misconceptions and misuse
Although the CHA 2 DS 2 -VASc score is widely used to guide decision-making on prescribing OAC for stroke prevention, it needs to be emphasised that like most clinical factorbased risk scores (whether in AF or non-AF), this score only has a modest predictive value for stroke and thromboembolism. The real value of the CHA 2 DS 2 -VASc score lies in a having straightforward and physician-friendly way of identifying 'truly' low risk patients (<1.0% annual risk of stroke) who do not need anticoagulation (i. CHA 2 DS 2 -VASc=0 and women with CHA 2 DS 2 -VASc=1 (for sex category only)). 6 Consequently, OAC should be offered to all AF patients as the default practice unless the AF patient is defined as 'truly low risk'. 2 Nevertheless, the CHA 2 DS 2 -VASc score is a cluster of common risk factors, and it is therefore unsurprising to find out that its components increase the risk of stroke, even in the absence of AF, given that AF is not the only reason for stroke. Similarly, patients with no AF history at baseline may have higher risk of stroke than those with AF, assuming that AF subjects should be anticoagulated, while many of those without prior AF may be undiagnosed and untreated. 7, 8 
AF prevalence
The major bias of most of the studies assessing the impact of stroke prediction (as per CHA 2 DS 2 -VASc score) on clinical outcomes is the uncertainty of 'absence of AF'. In the present analysis, 11.2% of patients had prior history of AF and in the systematic review, AF incidence was reported by only 13 studies. 1 In addition, these are only baseline data, and no data are available on AF incidence during the observation period.
Importantly, all components of CHA 2 DS 2 -VASc score are also risk factors for AF development and AF incidence is closely related to applied arrhythmia search strategies and the intensity of monitoring.
What about other scenarios? AF is commonly detected by cardiac implantable electronic devices (CIEDs). These episodes are frequently called preclinical, subclinical or asymptomatic AF, which may be very misleading and contribute to the misperception of their benign nature. There is however neither a 'preclinical' TIA nor a stroke.
Current medical technology allows us to detect as short as <1 s episodes of AF (Figure 1 ). This opens a completely new era of re-evaluation of real AF prevalence, at least in patients with CIEDs. For example, daily verification of remote transmissions shows AF can be detected in >80% of patients with cardiac resynchronisation defibrillators (CRT-Ds) during a three-year observation period. 9 Nevertheless, this is a specific patient population with advanced heart failure, implanted devices and multiple intracardiac electrodes, enlarged atria, frequent comorbid disease and may not reflect AF prevalence in the general population. On the other hand, the population-based incidence of AF has never been assessed with a high quality continuous electrocardiogram (ECG) monitoring for a (very) prolonged period.
There is also limited evidence on how much of detected AF is needed to increase the risk of stroke and thromboembolism. The shortest device-detected AF episodes of at least five minutes have been shown to increase stroke and mortality rates in the Mode Selection Trial (MOST) trial. 10 Whilst it remains debatable whether even shorter AF episodes are of clinical relevance, AF episodes <30 s were found in 23% of patients with recent cryptogenic TIA/ stroke during 21-day monitoring with mobile cardiac output telemetry. 11 Should anticoagulation not be offered to these patients for preventing recurrent stroke? What is our confidence on future AF burden in these patients? These important questions remain unanswered.
Current situation
The fact that ACS patients are at increased risk of stroke does not justify additional preventive strategies such as OAC to be introduced. ACS patients already require dual antiplatelet therapy (DAPT) to prevent stent thrombosis and there is limited evidence for any escalation of antithrombotic treatment in this population, also considering the fact that one-year stroke rates are not high enough to justify OAC. Of the OACs, only rivaroxaban at the low dose of 2.5 mg twice daily versus placebo plus DAPT in ACS patients has been shown to reduce the composite primary end point of death from cardiovascular causes, myocardial infarction, or stroke in the ATLAS ACS 2-TIMI 51 trial. 12 However, patients with prior intracranial haemorrhage, stroke or TIA on DAPT were excluded and those ⩾75 years of age constituted only less than 9% of study population. In addition, despite decrease in mortality and myocardial infarction rates, rivaroxaban (versus placebo) actually increased rates of stroke (hazard ratio (HR) 1.13; 95% confidence interval (CI); 0.74-1.73; p=0.56) and intracranial haemorrhage (HR 2.83; 95% CI; 1.02-7.86; p=0.04). 12 In conclusion, every effort should be made to keep looking for AF in ACS patients to allow clinicians to provide a guided patient-tailored therapy, as this population is at high risk of arrhythmia development and AF frequently remains undiagnosed and untreated. Importantly, patients with already diagnosed AF often view a stroke "as a fate worse than death", and may accept 4 major bleeds just to avoid one disabling stroke. 13, 14 Only then can the burden of stroke and thromboembolism be reduced.
